The results of two clinical trials show that the risk of legs in legs and feet is double in patients with type 2 diabetes with the new drug of the pharmaceutical.
Johnson & Amp;Johnson must add new warnings in his diabetes medicine, marketed under the name of Invokana, for the risk of suffering legs and feet, as warned by the American drug agency (FDA).
According to the report, the final results of two clinical trials show that legs of legs and feet occur twice frequency in patients with type 2 diabetes, treated with the Johnson & AMP medication;Johnson.
"They must include the" alert box "to identify severe possible side effects" in this sense, one of the FDA's requirements is to include an "alert box", identification that is reserved for the most serious adverse effects possible with the takingof a medicine.
In addition, from the American agency they urge patients who take Canagagzine to notify their doctors immediately if they develop a new pain or sensitivity, sores, ulcers or infections in the legs or feet.
As for professionals, the FDA requests that before prescribing this medicine, take into account the factors that can predispose patients at the risk of amputations, which includes a history of previous amputation, peripheral vascular disease, neuropathy, ulcers or footdiabetic.